伴有明显血小板增多症的环形铁粒幼细胞难治性贫血存在JAK2突变，并表现出骨髓增殖和骨髓发育异常特征的重叠。 - Suppr

Suppr

超能文献

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.

作者信息

Wang S A, Hasserjian R P, Loew J M, Sechman E V, Jones D, Hao S, Liu Q, Zhao W, Mehdi M, Galili N, Woda B, Raza A

出版信息

Leukemia. 2006 Sep;20(9):1641-4. doi: 10.1038/sj.leu.2404316. Epub 2006 Jul 27.

DOI:10.1038/sj.leu.2404316

PMID:16871284

Abstract

摘要

相似文献

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.

Leukemia. 2006 Sep;20(9):1641-4. doi: 10.1038/sj.leu.2404316. Epub 2006 Jul 27.

Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Haematologica. 2006 May;91(5):719-20.

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.

Leukemia. 2008 Jun;22(6):1295-8. doi: 10.1038/sj.leu.2405054. Epub 2007 Dec 6.

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Haematologica. 2008 Jan;93(1):34-40. doi: 10.3324/haematol.11581.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Blood. 2006 Oct 1;108(7):2173-81. doi: 10.1182/blood-2006-02-005751. Epub 2006 Jun 1.

High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Leukemia. 2006 Nov;20(11):2067-70. doi: 10.1038/sj.leu.2404405. Epub 2006 Sep 21.

The JAK2 V617F mutation is rare in RARS but common in RARS-T.

Leukemia. 2006 Nov;20(11):2060-1. doi: 10.1038/sj.leu.2404373. Epub 2006 Aug 24.

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.

Rom J Morphol Embryol. 2013;54(4):1177-82.

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.

Leukemia. 2005 Dec;19(12):2359-60. doi: 10.1038/sj.leu.2403989.

The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.

Leukemia. 2006 Jun;20(6):1165. doi: 10.1038/sj.leu.2404196.

引用本文的文献

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

BMC Cancer. 2022 Sep 24;22(1):1013. doi: 10.1186/s12885-022-10073-w.

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.

Blood Cancer J. 2022 Feb 1;12(2):26. doi: 10.1038/s41408-022-00622-8.

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.

Front Oncol. 2021 Nov 16;11:778741. doi: 10.3389/fonc.2021.778741. eCollection 2021.

Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.

Mod Pathol. 2022 Apr;35(4):470-479. doi: 10.1038/s41379-021-00961-0. Epub 2021 Nov 13.

Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis.

Hematol Transfus Cell Ther. 2018 Oct-Dec;40(4):385-388. doi: 10.1016/j.htct.2018.02.005. Epub 2018 Apr 14.

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Oncotarget. 2017 Jun 6;8(23):37239-37249. doi: 10.18632/oncotarget.16744.

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13.

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.

Leukemia. 2014 Apr;28(4):958-61. doi: 10.1038/leu.2014.8. Epub 2014 Jan 10.

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms.

Exp Ther Med. 2013 May;5(5):1332-1338. doi: 10.3892/etm.2013.975. Epub 2013 Feb 26.

Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia.

Case Rep Hematol. 2013;2013:718480. doi: 10.1155/2013/718480. Epub 2013 Apr 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验